Global Autoimmune Partnering 2014-2019: Deal trends, players and financials

Be the first to review this product

Availability: In stock

$2,995.00
Global Autoimmune Partnering 2014-2019: Deal trends, players and financials
Publication date Jun 2019
Publisher Current Partnering
Number of pages 500+
Report edition On demand
Product code CP2228
ISBN n/a
Product type Research report
Available formats PDF

OR

Global Autoimmune Partnering 2014 to 2019 provides the full collection of Autoimmune disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.

 

  • Trends in Autoimmune partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Autoimmune partnering agreement structure
  • Autoimmune partnering contract documents
  • Top Autoimmune deals by value
  • Most active Autoimmune dealmakers

                   

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

                          

The report takes readers through the comprehensive Autoimmune disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Autoimmune deals.

 

The report includes coverage of the following autoimmune diseases:

 

Multiple sclerosis, Restless leg syndrome, Dermatitis, Eczema, Alopecia, Psoriasis, Celiac disease, Inflammatory bowel disease, Crohn’s disease, Ulcerative colitis, Glomerulonephritis, Endometriosis, Immune thrombocytopenic purpura, Neutropenia, Graft versus host disease, Scleroderma, Systemic lupus erythematosus, Addison’s disease, Diabetes Type 1, Ankylosing spondylitis, Juvenile arthritis, Psoriatic arthritis, Rheumatoid arthritis, Uveitis, Narcolepsy, Chronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Sarcoidosis, Meniere's disease, and other autoimmune disorders.

 

The report presents financial deal terms values for Autoimmune deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

 

The initial chapters of this report provide an orientation of Autoimmune dealmaking trends.

 

Chapter 1 provides an introduction to the report.

 

Chapter 2 provides an overview of the trends in Autoimmune dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

 

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

                              

Chapter 4 provides a review of the leading Autoimmune deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Autoimmune dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

                                                                       

Chapter 5 provides comprehensive access to Autoimmune deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive directory of all Autoimmune partnering deals by specific Autoimmune target announced since 2014. The chapter is organized by specific Autoimmune therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In addition, a comprehensive appendix is provided with each report of all Autoimmune partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in Autoimmune partnering and dealmaking since 2014.      

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Autoimmune technologies and products.

Global Autoimmune Partnering 2014 to 2019 provides the reader with the following key benefits:

 

  • In-depth understanding of Autoimmune deal trends since 2014
  • Access Autoimmune deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Autoimmune partner companies
  • Comprehensive access to over 700 links to actual Autoimmune deals entered into by the world’s biopharma companies
  • Indepth review of Autoimmune deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Autoimmune opportunities
  • Uncover companies actively partnering Autoimmune opportunities

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in Autoimmune dealmaking

 

2.1. Introduction

2.2. Autoimmune partnering over the years        

2.3. Autoimmune partnering by deal type

2.4. Autoimmune partnering by industry sector

2.5. Autoimmune partnering by stage of development

2.6. Autoimmune partnering by technology type

2.7. Autoimmune partnering by therapeutic indication

 

Chapter 3 –Financial deal terms for Autoimmune partnering

 

3.1. Introduction

3.2. Disclosed financials terms for Autoimmune partnering

3.3. Autoimmune partnering headline values

3.4. Autoimmune deal upfront payments

3.5. Autoimmune deal milestone payments

3.6. Autoimmune royalty rates

 

Chapter 4 – Leading Autoimmune deals and dealmakers

 

4.1. Introduction

4.2. Most active in Autoimmune partnering

4.3. List of most active dealmakers in Autoimmune        

4.4. Top Autoimmune deals by value

 

Chapter 5 – Autoimmune contract document directory

                                            

5.1. Introduction

5.2. Autoimmune partnering deals where contract document available

 

Chapter 6 – Autoimmune dealmaking by therapeutic target

 

6.1. Introduction

6.2. Deals by Autoimmune therapeutic target

 

Appendices

 

Appendix 1 – Directory of Autoimmune deals by company A-Z since 2014

Appendix 2 – Directory of Autoimmune deals by deal type since 2014

Appendix 3 – Directory of Autoimmune deals by stage of development since 2014

Appendix 4 – Directory of Autoimmune deals by technology type since 2014

Further reading on dealmaking

Deal type definitions

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from CurrentPartnering

 

Table of figures

 

Figure 1: Autoimmune partnering since 2014

Figure 2: Autoimmune partnering by deal type since 2014

Figure 3: Autoimmune partnering by industry sector since 2014

Figure 4: Autoimmune partnering by stage of development since 2014

Figure 5: Autoimmune partnering by technology type since 2014

Figure 6: Autoimmune partnering by indication since 2014

Figure 7: Autoimmune deals with a headline value

Figure 8: Autoimmune deals with upfront payment values

Figure 9: Autoimmune deals with milestone payment

Figure 10: Autoimmune deals with royalty rates

Figure 11: Active Autoimmune dealmaking activity since 2014

Figure 12: Top Autoimmune deals by value since 2014

Pricing options

  • $2,995: single-user
  • $4,495: multi-user
  • $8,995: single site license
  • $14,995: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

Write Your Own Review

Only registered users can write reviews. Please, log in or register

© 2019 Wildwood Ventures Ltd.